Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01425359 · ClinicalTrials.gov registry record · Phase 4
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
A Phase 4 study of Coronary Artery Disease and Type 2 Diabetes Mellitus, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 949
- Enrollment target
- 20
- Study locations
NCT01425359 is a Phase 4 study of Coronary Artery Disease and Type 2 Diabetes Mellitus that has completed, run by Gilead Sciences. The registered enrollment target is 949 participants, below the 1,283-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT01425359, a Phase 4 study of Coronary Artery Disease and Type 2 Diabetes Mellitus, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 949 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM), and whether ranolazine can reduce the frequency of angina (chest pain) attacks, compared to a placebo. Subjects will be asked to record their daily angina episodes in a diary at the end of each study day. Ranolazine is approved for the treatment of chronic angina, and is not approved for the treatment of T2DM.
Conditions Studied
Interventions
- DRUG Ranolazine
- DRUG Ranolazine placebo
Study Locations (20)
California
- Merced Heart Associates - Merced
- Spectrum Clinical Research Institute, Inc - Moreno Valley
- Sacramento Heart and Vascular Research Center - Sacramento
Florida
- South Florida Research Solutions, LLC - Hollywood
- Baptist Heart Specialist - Jacksonville
- Clinical Research of Central Florida - Winter Haven
Georgia
- Masters of Clinical Research, Inc. - Augusta
- Columbus Cardiology Associates - Columbus
Kentucky
- Central Cardiology Associates - Elizabethtown
- Research Integrity, LLC - Owensboro
Louisiana
- Alexandria Cardiology Clinic - Alexandria
- Clinical Trials Management, LLC - Mandeville
Tennessee
- Kore CV Research - Jackson
- Wellmont Cardiovascular Associates Heart Institute - Johnson City
Texas
- Med-Tech Research - Houston
- Humble Cardiology Associates - Humble
Arkansas
- Cardiology and Medicine Clinic - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 949 participants |
| Start Date | 2011-09 |
| Est. Completion | 2012-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01425359
The ClinicalTrials.gov registry entry for NCT01425359 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 949 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,283-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (26% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Ranolazine is the first listed.
NCT01425359 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01425359 about?
NCT01425359 is a clinical study titled "Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina". This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus (T2DM), and whether ranolazine can reduce the frequency of angina (ches...
What is the current status of trial NCT01425359?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 949 participants. The study started on 2011-09. Estimated completion is 2012-10.
What conditions does trial NCT01425359 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Type 2 Diabetes Mellitus, Angina Pectoris.
What interventions are being tested in trial NCT01425359?
The interventions under investigation include: Ranolazine (DRUG), Ranolazine placebo (DRUG).
Who is sponsoring clinical trial NCT01425359?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01425359 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
RECRUITING · Phase 4
-
The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial
RECRUITING · Phase 4
-
Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study
RECRUITING · Phase 4
-
Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention
RECRUITING · Phase 4
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
RECRUITING · Phase 4
-
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.